The Role of Ursodeoxycholic Acid Administration During the COVID-19 Pandemic: A Questionnaire Survey
In December 2022, China classified COVID-19 as a category B infectious disease. This ended 2 years of close epidemiological surveillance of COVID-19. The objective of this questionnaire was to assess the infection status in the COVID-19 pandemic since December in Henan Province, China, and the preva...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/cjid/4601882 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592921537282048 |
|---|---|
| author | Cheng Zhou Ran Jia Jinqiu Yang Tong Liu Xiaoyan Liu Lin Yang Wenxia Zhao |
| author_facet | Cheng Zhou Ran Jia Jinqiu Yang Tong Liu Xiaoyan Liu Lin Yang Wenxia Zhao |
| author_sort | Cheng Zhou |
| collection | DOAJ |
| description | In December 2022, China classified COVID-19 as a category B infectious disease. This ended 2 years of close epidemiological surveillance of COVID-19. The objective of this questionnaire was to assess the infection status in the COVID-19 pandemic since December in Henan Province, China, and the prevalence of infection in people who were taking ursodeoxycholic acid (UDCA) during this period. We distributed questionnaires to patients attending the gastroenterology clinic at the First Affiliated Hospital of Henan University of Chinese Medicine. The questionnaire lasted for 3 weeks and a total of 660 were collected, of which the number of people taking UDCA was 70. This is the first investigation into the rate of infection among those taking UDCA during the time of the COVID-19 pandemic. Our results showed that the overall infection rate among those taking UDCA was 71.43% (n = 50), with a 10% (n = 7) rate of asymptomatic infections, which was significantly lower than the 85.42% (n = 504) and 6.27% (n = 37) rates among respondents who did not take. The administration of UDCA showed a trend toward reducing the rate of COVID-19 infection, but the difference was not statistically significant when compared to patients with shorter durations of medication use. While less than 30% of participants remained uninfected during the study period, indicating a potential protective effect, it is important to note that complete prevention of SARS-CoV-2 infection by UDCA was not observed. |
| format | Article |
| id | doaj-art-48a4098a2671474cb6359ef3a1ac81f6 |
| institution | Kabale University |
| issn | 1918-1493 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-48a4098a2671474cb6359ef3a1ac81f62025-01-21T00:00:01ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1918-14932025-01-01202510.1155/cjid/4601882The Role of Ursodeoxycholic Acid Administration During the COVID-19 Pandemic: A Questionnaire SurveyCheng Zhou0Ran Jia1Jinqiu Yang2Tong Liu3Xiaoyan Liu4Lin Yang5Wenxia Zhao6Department of OncologyKey Laboratory of Liver DiseaseKey Laboratory of Liver DiseaseKey Laboratory of Liver DiseaseKey Laboratory of Liver DiseaseDepartment of Hepatobiliary SurgeryKey Laboratory of Liver DiseaseIn December 2022, China classified COVID-19 as a category B infectious disease. This ended 2 years of close epidemiological surveillance of COVID-19. The objective of this questionnaire was to assess the infection status in the COVID-19 pandemic since December in Henan Province, China, and the prevalence of infection in people who were taking ursodeoxycholic acid (UDCA) during this period. We distributed questionnaires to patients attending the gastroenterology clinic at the First Affiliated Hospital of Henan University of Chinese Medicine. The questionnaire lasted for 3 weeks and a total of 660 were collected, of which the number of people taking UDCA was 70. This is the first investigation into the rate of infection among those taking UDCA during the time of the COVID-19 pandemic. Our results showed that the overall infection rate among those taking UDCA was 71.43% (n = 50), with a 10% (n = 7) rate of asymptomatic infections, which was significantly lower than the 85.42% (n = 504) and 6.27% (n = 37) rates among respondents who did not take. The administration of UDCA showed a trend toward reducing the rate of COVID-19 infection, but the difference was not statistically significant when compared to patients with shorter durations of medication use. While less than 30% of participants remained uninfected during the study period, indicating a potential protective effect, it is important to note that complete prevention of SARS-CoV-2 infection by UDCA was not observed.http://dx.doi.org/10.1155/cjid/4601882 |
| spellingShingle | Cheng Zhou Ran Jia Jinqiu Yang Tong Liu Xiaoyan Liu Lin Yang Wenxia Zhao The Role of Ursodeoxycholic Acid Administration During the COVID-19 Pandemic: A Questionnaire Survey Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | The Role of Ursodeoxycholic Acid Administration During the COVID-19 Pandemic: A Questionnaire Survey |
| title_full | The Role of Ursodeoxycholic Acid Administration During the COVID-19 Pandemic: A Questionnaire Survey |
| title_fullStr | The Role of Ursodeoxycholic Acid Administration During the COVID-19 Pandemic: A Questionnaire Survey |
| title_full_unstemmed | The Role of Ursodeoxycholic Acid Administration During the COVID-19 Pandemic: A Questionnaire Survey |
| title_short | The Role of Ursodeoxycholic Acid Administration During the COVID-19 Pandemic: A Questionnaire Survey |
| title_sort | role of ursodeoxycholic acid administration during the covid 19 pandemic a questionnaire survey |
| url | http://dx.doi.org/10.1155/cjid/4601882 |
| work_keys_str_mv | AT chengzhou theroleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT ranjia theroleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT jinqiuyang theroleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT tongliu theroleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT xiaoyanliu theroleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT linyang theroleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT wenxiazhao theroleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT chengzhou roleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT ranjia roleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT jinqiuyang roleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT tongliu roleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT xiaoyanliu roleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT linyang roleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey AT wenxiazhao roleofursodeoxycholicacidadministrationduringthecovid19pandemicaquestionnairesurvey |